Esteban R
Liver Unit, Hospital General Vall d'Hebron, Universitat Autonoma de Barcelona, Spain.
J Hepatol. 1993;17 Suppl 3:S67-71. doi: 10.1016/s0168-8278(05)80427-1.
The availability of the anti-HCV assay has confirmed most of the suspicions and predictions regarding the epidemiology of NANB hepatitis virus made before the discovery of HCV. It is now clear that HCV is responsible for the majority of cases of post-transfusion and sporadic NANB hepatitis, as well as of most cases of unidentified chronic liver disease. It seems plausible that HCV may act as a negative co-factor in other chronic liver diseases, especially those caused by alcohol, other hepatitis viruses, and so-called 'autoimmune hepatitis'. The issue of perinatal and sexual transmission of HCV has not yet been clarified, and further studies are urgently needed. Finally, the high prevalence of anti-HCV detected in HCC suggests that HCV is a major co-factor in the development of HCC and again raises the issue of viral persistence and neoplastic transformation, an issue that for HBV has not yet been elucidated.
抗丙型肝炎病毒检测方法的出现证实了在丙型肝炎病毒发现之前对非甲非乙型肝炎病毒流行病学所做的大多数怀疑和预测。现在很清楚,丙型肝炎病毒是大多数输血后和散发性非甲非乙型肝炎病例的病因,也是大多数不明原因慢性肝病病例的病因。丙型肝炎病毒可能在其他慢性肝病中作为负协同因子起作用,尤其是由酒精、其他肝炎病毒和所谓“自身免疫性肝炎”引起的慢性肝病,这似乎是合理的。丙型肝炎病毒的围产期传播和性传播问题尚未阐明,迫切需要进一步研究。最后,在肝癌中检测到的抗丙型肝炎病毒高流行率表明,丙型肝炎病毒是肝癌发生的主要协同因子,这再次引发了病毒持续存在和肿瘤转化的问题,而乙型肝炎病毒的这一问题尚未得到阐明。